BCG June 27, 2024
Biopharmaceutical companies have long worked to expand access to their products, with millions of patients around the world benefiting from life-saving therapies. Such efforts, aligned with the industry’s mission and typically driven through charitable and social programs, aim to narrow the sizeable health disparities that exist globally.
But health equity initiatives have not typically been an integral part of addressing another industry imperative: meeting market and shareholder expectations for steady, healthy growth of the business. Consequently, biopharma’s efforts to expand equity remain relatively limited in scale and impact.
That is beginning to change. Increasingly, companies are building a strong business case for addressing health inequity, both at the country level and between wealthy nations and low- and middle-income countries (LMICs)....
Today's Sponsors
Today's Sponsor